Table 2.
Antibody response to three doses of mRNA-based SARS-CoV-2 vaccine in 78 lung transplant recipients.
| Positive response (n = 48) | Negative response (n = 30) | p-value | |
|---|---|---|---|
| Female (%) | 23 (48) | 15 (50) | 0.86 |
| Median age (IQR) | 61 (50–65) | 63 (55–68) | 0.09 |
| Median years since transplantation (IQR) | 4.28 (1.87–8.06) | 5.36 (1.62–10.52) | 0.85 |
| Non-standard immunosuppressive therapy (%) | 4 (8) | 4 (13) | 0.48 |
| Tacrolimus (%) | 47 (98) | 30 (100) | 1.00 |
| Sirolimus added to tacrolimus (%) | 2 (4) | 0 (0) | 0.52 |
| Mycophenolate mofetil (%) | 47 (98) | 26 (87) | 0.08 |
|
7 (15) | 4 (13) | |
|
37 (77) | 17 (57) | |
|
2 (7) | 6 (10) | |
| Prednisone (%) | 48 (100) | 30 (100) | 0.39 |
|
11 (23) | 4 (13) | |
|
35 (73) | 23 (77) | |
|
2 (4) | 3 (10) | |
| COVID-19 prior to vaccination (%) | 12 (25) | 1 (3) | 0.01 |
| Positive SARS-CoV-2 antibodies prior to first vaccination (%) * | 9 (19) | 1 (3) | 0.08 |
| Positive SARS-CoV-2 antibodies prior to second vaccination (%) # | 15 (31) | 1 (3) | 0.01 |
| Positive SARS-CoV-2 antibodies after second vaccination (%) | 25 (52) | 2 (7) | <0.001 |
IQR = interquartile range. Percentages for subcategories are based on the number of patients for whom that parameter was available. * available in 77 patients. # available in 76 patients. Positive response defined as an IgG concentration > 33.8 BAU/ml.